Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.580 +0.120 (+8.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Friday's after-hours session.
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
Via Benzinga
What's going on in today's after hours session
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts and pipeline challenges. 
Via Benzinga
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Get insights into the top gainers and losers of Monday's after-hours session.
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Here are the top movers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The company plans further data analysis. 
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are gapping on Monday?
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Unusual volume stocks in Wednesday's session
On Wednesday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
 
Via Benzinga
This Illumina Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
The market is filled with gapping stocks in Monday's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Dow Gains 100 Points; McDonald's Shares Rise After Q4 Results
 
Via Benzinga
Topics Stocks
Monday's pre-market session: top gainers and losers
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed bexotegrast reduced lung collagen. 
Via Benzinga
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.